• Lutte contre les cancers

  • Observation

  • Col de l'utérus

Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study

Menée en population dans la région nord-est de l'Angleterre, cette étude évalue, sur la période 2000-2009, l'évolution de l'incidence du cancer du col de l'utérus chez les jeunes femmes âgées de 20 à 29 ans, la compare à celle constatée chez les femmes plus âgées et identifie les facteurs associés à cette évolution

Background : The commencing age of cervical screening in England was raised from 20 to 25 years in 2004. Cervical cancer incidence in young women of England is increasing. It is not clear if this is due to either greater exposure to population risk factors or reduced cervical screening. Methods : We measured if the relative risk of cervical cancer in younger women (20–29 years) of the north-east of England (NE) differed to that of women aged 30yrs and above since 2004. We also measured average annual percentage change (AAPC) in the 3 yr moving average incidence for all age-groups. Regional screening coverage rate and population risk factors were reviewed. Comparisons were made with Wales where screening continues to commence from the age of 20 yrs. Results : Cervical cancer incidence in women aged 20–29 increased annually by an average of 10.3% between 2000 and 2009. The rise in women aged 30–39 was less steep (3.5%/year) but no significant rise was observed in women aged 40–49. Socioeconomic factors remained stable or improved during the time period except for the incidence of chlamydia, herpes simplex and in particular, genital warts, which increased significantly in young women. Data from Wales show similar results. Conclusion : The incidence of cervical cancers in young women of the NE is increasing. The rise in incidence is unrelated to the change in screening policy in 2004. Close monitoring of incidence in young women and a greater attempt to reverse the current decline in screening coverage of women aged 25–29 years are recommended.

British Journal of Cancer 2012

Voir le bulletin